Introduction
============

Definitive concurrent chemoradiotherapy (CCRT) has become the standard treatment for patients with N3-positive stage IIIB (N3-IIIB) non-small cell lung cancer (NSCLC) \[[@b1-crt-2014-131]-[@b4-crt-2014-131]\]. Delivery of high radiation dose, which is usually recommended for improved locoregional control and survival \[[@b5-crt-2014-131]\], is often limited by the risk of lung toxicity, which presents as radiation pneumonitis and subsequent pulmonary fibrosis \[[@b6-crt-2014-131],[@b7-crt-2014-131]\]. The extent of metastatic regional lymph nodes (LN) in patients with N3-IIIB NSCLC is quite heterogeneous \[[@b8-crt-2014-131]\], and it often becomes difficult to safely cover the whole disease extent within the high radiation dose volume when using conventional 3-dimensional conformal radiation therapy (3D-CRT) technique. Metastasis to the supraclavicular lymph node (SCN) from the lower lobe primary tumor is a typical problematic example. Introduction of the intensity-modulated radiation therapy (IMRT) technique has greatly improved the target coverage at high radiation dose while sparing normal lung tissue \[[@b9-crt-2014-131]-[@b11-crt-2014-131]\]. Previous studies that employed IMRT were more or less successful at achieving favorable clinical outcomes in terms of locoregional control and survival and reducing the incidences of pulmonary and esophageal toxicities, among which the proportion of patients with N3 or IIIB disease accounted for 32%-60% \[[@b12-crt-2014-131]-[@b14-crt-2014-131]\]. Based on these studies, the use of IMRT for treatment of patients with stage III NSCLC has become increasingly popular \[[@b15-crt-2014-131]\].

The use of IMRT is still limited in Korea, mainly because the national health insurance plan covers only the 3D-CRT technique and does not reimburse the cost of IMRT during treatment of patients with NSCLC. Given this limitation, few clinical studies on the use of IMRT for lung cancer patients have been conducted in Korea \[[@b16-crt-2014-131]\]. Since May of 2010, the authors at Samsung Medical Center (SMC) have been using IMRT to treat patients with extensive NSCLC. Based on their known disease extent, these patients were believed to be at excessive risk of pulmonary toxicity if treated with conventional 3D-CRT. This study was conducted to comparatively evaluate treatment outcomes based on the radiation therapy (RT) techniques chosen (IMRT vs. 3D-CRT) for evaluation of N3-IIIB NSCLC patients receiving definitive CCRT.

Materials and Methods
=====================

From May 2010 to November 2012, 81 patients with newly diagnosed, pathologically confirmed N3-IIIB NSCLC were treated with definitive CCRT at SMC. Since trimodality therapy strategy, which includes surgical resection following neoadjuvant CCRT, has been the primary treatment option for N2-IIIA patients at SMC \[[@b17-crt-2014-131]\], patients with N3-IIIB disease constituted the majority of those receiving definitive CCRT. Among these, two patients received curative surgical resection following definitive CCRT, and another two received a combination of 3D-CRT and IMRT. After excluding these four patients, we retrospectively reviewed the medical records of 77 patients who were the basis of the current study. The RT techniques were selected individually based on the known disease extent, performance and cardiopulmonary functional status of the patients, and the subsequent estimated risk of pulmonary toxicity. When the estimated V~20~ exceeded 40%, the mean lung dose exceeded 25 Gy, and/or the maximum spinal cord dose exceeded 50 Gy if treated with conventional 3D-CRT, they were offered the IMRT option. It was explained to all the IMRT candidate patients that IMRT was not covered by the Korean insurance policy, and they were offered alternative option of induction chemotherapy followed by sequential RT in case the IMRT cost was not affordable. All IMRT candidate patients agreed to pay the extra-cost, and the current study was approved by the Institutional Review Board of Samsung Medical Center (2013-08-027).

The initial diagnosis of NSCLC was pathologically confirmed in all patients based on either bronchoscopy or percutaneous fine-needle aspiration and biopsy. The diagnostic and staging work-ups included complete history and physical examination, simple chest radiographs, chest computed tomography (CT) scan, routine blood tests, and ^18^fluoro-deoxyglucose positron emission tomography (PET) or PET/CT scan. For accurate nodal staging, fine-needle aspiration from the SCN was performed in 33 patients (42.9%), endobronchial ultrasound-guided transbronchial needle aspiration in 29 (37.7%), and mediastinoscopic biopsy in nine (9.1%). N3 stage assignment was made primarily based on clinical judgment without histologic confirmation in 15 patients (19.5%) who showed abnormal findings on PET/CT scan and were at very high risk to undergo any invasive procedures.

For treatment planning, contrast enhancing simulation CT scans of all patients were conducted. Simulation CT scans were typically performed in the supine position at a thickness of 2.5-5 mm. The gross tumor volume (GTV) was defined as the volume of the tumor identified based on all available clinical information, including radiologic imaging, PET scan, bronchoscopy, and mediastinoscopy. The clinical target volume (CTV) was delineated by a 5-mm margin extending in all directions from the GTV, and the margins were modified in accordance with the adjacent organs if necessary. The internal target volume was delineated by combining all GTVs and CTVs delineated on each respiratory phase based on 4-dimensional computed tomography (4D-CT), which was acquired in 29 patients (37.7%). Elective irradiation of the clinically uninvolved lymph node was not allowed principally. A 5-8 mm margin extension around the CTV was included to generate the planning target volume. The Pinnacle^3^ system (ver. 8.0, Philips Medical Systems, Madison, WI) was used to calculate the radiation dose.

During the study period, 48 patients (62.3%) were treated with 3D-CRT (group I) and 29 (37.7%) with IMRT (group II). The median RT dose prescribed to the CTV was 66 Gy in 33 fractions over 6.5 weeks. The 3D-CRT plan was typically composed of three or four beams of 4-, 6-, or 10-MV photons from a linear accelerator (Varian Medical System, Palo Alto, CA). The IMRT plan was mainly composed of six median coplanar beams of 6-MV photons using the step-and-shoot method. Whenever feasible and indicated, the second CT simulation and adaptive re-plan was generated to accommodate tumor regression and reduce the normal tissue toxicity, typically at fractions of 20-23. The normal tissue constraints used were as follows: maximum spinal cord dose \< 46 Gy; relative lung volumes receiving 20 Gy/5 Gy \< 35%/\< 65%; and the mean lung dose \< 20 Gy. The most common concurrent chemotherapeutic regimen was weekly paclitaxel or docetaxel plus cisplatin or carboplatin, which was administered to 67 patients (87.0%). Ten of these patients received additional consolidation chemotherapy following CCRT. The remaining ten patients (13.0%) received pemetrexed or etoposide plus cisplatin, while nine of these patients received consolidation chemotherapy.

The first follow-up and response evaluation was scheduled at 1 month after completion of CCRT and included a chest CT scan. Subsequent follow-up evaluations were conducted at 3-4 month intervals thereafter, and included alternating chest CT and whole-body PET/CT scans. The early toxicities of treatment-related pneumonitis (TRP) and esophagitis were graded using the Common Terminology Criteria for Adverse Events (CTCAE), ver. 4.0. The primary endpoints were the progression-free survival (PFS) and the overall survival (OS), while the secondary endpoints were the in-field locoregional control (LRC) and patterns of disease progression. All intervals were calculated from the dates of the CCRT start until the events or the latest follow-up. In-field locoregional progression was defined as disease progression within the irradiated volume inside the thorax, and included the ipsilateral hilum, ipsilateral and/or contralateral mediastinum, and ipsilateral and/or contralateral SCN, but not hematogenous lung-to-lung metastasis.

A chi-square test was used to compare the patients' clinical characteristics and the dose-volume parameters based on the RT techniques used. A t test was used to compare continuous variables such as age, forced expiratory volume in 1 second, and tumor size. The rates of PFS, OS, and LRC were calculated and compared using the Kaplan-Meier method and the log-rank test, respectively. Factors having a p-value of \< 0.2 upon univariate analysis were entered into Cox proportional hazards regression analysis. A p-value of ≤ 0.05 was considered statistically significant, and the SAS software (ver. 9.1.3, SAS Institute Inc., Cary, NC) was used for statistical analyses.

Results
=======

The clinical characteristics based on the RT techniques are summarized in [Table 1](#t1-crt-2014-131){ref-type="table"}. The median age of all patients was 60 years (range, 40 to 80 years). Age, sex, smoking history, performance status, and clinical T classification did not differ between groups. Adenocarcinoma was the most common histology (53 patients, 68.8%), followed by squamous cell carcinoma (18 patients, 23.4%). The median tumor size measured on the initial CT was 3.8 cm (range, 1.0 to 12.2 cm). Group II (IMRT) patients had significantly more frequent primary tumors located in the lower lobes (p=0.001) and SCN involvement (p=0.011) than group I (3D-CRT). Among 50 patients with SCN involvement, 16 had primary tumors located in the lower lobes, which was also more frequent in group II than in group I (13/24 patients, 54.2% vs. 3/26 patients, 11.5%). The median CTV of all patients was 288.0 cm^3^ (range, 89.3 to 1,543.3 cm^3^). Although the median CTV tended to be larger in group II than group I (3D-CRT), this difference was not statistically significant according to a t test (p=0.706) ([Table 2](#t2-crt-2014-131){ref-type="table"}). When the CTVs were stratified into groups (\< 300 cm^3^ vs. ≥ 300 cm^3^), group II was associated with larger CTV more frequently than group I (p=0.043). Since patients receiving IMRT generally had a greater extent of disease, the mean lung and heart doses were higher in group II than in group I. However, the normal tissue doses generally met the constraints described above. Among the 16 patients with SCN metastasis from the lower lobe primary tumors, dose-volume parameters for the lungs and esophagus were generally similar ([Fig. 1](#f1-crt-2014-131){ref-type="fig"}).

The median follow-up duration was 21.7 months (range, 2.3 to 43.1 months). During the follow-up period, 45 patients (58.4%) experienced disease progression ([Table 3](#t3-crt-2014-131){ref-type="table"}). The most common first failure pattern was distant metastasis observed in 39 patients (50.6%), followed by locoregional progression in 13 patients (16.9%). Among 13 patients with locoregional failure, nine showed progression within the RT volume, six from group I and three from group II. There were seven patients (9.1%) who presented with both locoregional and distant progression. The organs involved via distant metastasis were the lung in 12 patients, the brain in nine, bone in eight, and the liver in five. The median duration of PFS was 11.1 months, and the 1- and 2-year rates of PFS were 47.9% and 38.7%, respectively ([Fig. 2](#f2-crt-2014-131){ref-type="fig"}). The 1- and 2-year rates of in-field LRC were 87.9% and 85.0%, respectively. A total of 18 patients (23.4%) died during the follow-up period. Pulmonary causes, such as pneumonia, pneumonitis, and acute respiratory distress syndrome, were responsible for the deaths of two patients, one from group I and the other from group II, while TRP was not the direct cause of death for two patients. In addition, one patient died of myocardial infarction. The 1- and 2-year rates of OS were 85.5% and 75.2%, respectively ([Fig. 2](#f2-crt-2014-131){ref-type="fig"}). The incidence of CTACE grade 3 esophagitis was 19.5%, which was not different between groups I and II (14.6% vs. 27.6%, p=0.163). Although patients receiving IMRT had significantly larger disease extent and received higher lung dose, the incidence of grade ≥ 2 pneumonitis was not higher in group II than group I (33.3% vs. 24.1%, p=0.393). Among the 16 patients with SCN metastasis from the lower lobe primary tumor, grade ≥ 2 pneumonitis developed in three patients, one from group I and two from group II. Grade 3 esophagitis occurred in four patients in group II.

The clinical outcomes based on the probable prognostic factors are summarized in [Tables 4](#t4-crt-2014-131){ref-type="table"} and [5](#t5-crt-2014-131){ref-type="table"}. According to univariate analyses, IMRT technique (p=0.001), age \< 60 years (p=0.019), and non-squamous cell carcinoma histology (p=0.002) were associated with significantly poor PFS, while IMRT technique (p=0.007), SCN metastasis from the lower lobe primary tumor (p=0.019), and CTV ≥ 300 cm^3^ (p=0.001) were associated with significantly poor OS. Gender, clinical T stage, and SCN involvement itself were not of prognostic value to the clinical outcomes. No specific factor was known to have affected the in-field LRC. Based on multivariate analyses, IMRT technique (p=0.010) and age \< 60 years (p=0.032) were significant poor prognostic factors affecting the PFS. Interestingly, the RT technique was not a significant factor affecting the OS (p=0.197), while a CTV ≥ 300 cm^3^ was the only factor that had a significant effect on the OS (p=0.018).

Discussion
==========

Few studies have reported the treatment outcomes following IMRT for NSCLC \[[@b12-crt-2014-131]-[@b14-crt-2014-131],[@b16-crt-2014-131],[@b18-crt-2014-131]\]. These previous studies not only included patients with stage IIIB disease, but also those with stage IIIA and even stages I/II. Although the current study included only N3-IIIB patients, the disease extent was still quite heterogeneous because of differences in the location of metastatic LNs and the CTVs. Despite definitive CCRT being the standard treatment option for patients with N3-IIIB NSCLC, 3D-CRT cannot safely deliver high radiation doses cases of large disease extent, especially in those involving SCN metastasis from lower lobe primary tumors, because of the normal tissue toxicity risk. Based on previously conducted studies, IMRT could result in significantly lower levels of grade ≥ 3 TRP when compared with 3D-CRT, despite the large GTVs \[[@b12-crt-2014-131]\]. Furthermore, a subsequent study showed that IMRT with 4D-CT was associated with reduced toxicity and improved OS \[[@b13-crt-2014-131]\]. Following the median follow-up of 16.5 months, the 2-year rates of disease-free survival and OS were 38% and 46%, respectively \[[@b14-crt-2014-131]\].

Patients receiving IMRT in the current study had significantly more frequent SCN metastasis from the lower lobe primary tumor and significantly larger CTVs than those receiving 3D-CRT. Even though group II patients had a larger disease extent and were therefore subjected to higher normal tissue doses, the incidences of grade 3 esophagitis and grade ≥ 2 pneumonitis were not increased in this group based on the current study. Moreover, a comparable in-field LRC was achieved, while more frequent distant metastases occurred in patients receiving IMRT. While the 2-year rates of PFS and OS following definitive CCRT for patients with N3-IIIB NSCLC were 38.7% and 75.2%, respectively, the corresponding rates of patients receiving IMRT were 19.3% and 61.7%, respectively ([Table 4](#t4-crt-2014-131){ref-type="table"}). However, direct comparison of the clinical outcomes between groups I and II should be made with caution because of the evident heterogeneity of the clinical characteristics. Although patients receiving IMRT had unfavorable survival outcomes, this might have occurred because these patients already had more adverse prognostic factors than those receiving 3D-CRT. The PFS at 2 years reported in this study seems inferior to that of previous studies (19.3% vs. 38%). This difference might have been due to the heterogeneous patient population with respect to stage, tumor location, and extent of nodal involvement. One retrospective study of IMRT reported a 2-year OS rate of 58% in stage III patients \[[@b18-crt-2014-131]\], and the corresponding figure by the authors appears to be generally favorable when compared with the previous data. Taken together, IMRT could safely cover a larger disease extent than 3D-CRT, and yielded a favorable in-field LRC with no extra toxicity risk.

As shown in [Table 3](#t3-crt-2014-131){ref-type="table"}, the median time to progression following IMRT was only 6 months, and this was mostly due to early appearance of distant metastases. Interestingly, the OS was not as poor as the PFS in the current study. It is important to note that clinical outcomes following disease progression might be influenced by the availability of systemic treatment regimens, including targeting agents, which were not presented in detail in the current study. Although collection of biomarker data such as mutations in the epidermal growth factor receptor (*EGFR*) gene and/or anaplastic lymphoma kinase (*ALK*) gene was not the primary objective of the current study, 13 (24.5%) and five (9.4%) of 53 patients with adenocarcinoma exhibited *EGFR* gene mutations and *ALK* rearrangements, respectively. Furthermore, 16 of these 18 patients exhibited disease progression, mostly distant metastases. In patients with N2-positive NSCLC, *EGFR* mutation was shown to experience more frequent distant relapse and have worse PFS following preoperative CCRT and surgery at SMC \[[@b19-crt-2014-131]\]. CCRT accompanied by treatment with cetuximab, a monoclonal antibody targeting EGFR, has demonstrated promising outcomes in patients with stage III NSCLC \[[@b20-crt-2014-131],[@b21-crt-2014-131]\]. Moreover, favorable clinical outcomes have been reported in patients treated with the ALK tyrosine-kinase inhibitor, crizotinib \[[@b22-crt-2014-131]\]. Therefore, further improvement of clinical outcomes in the patients receiving definitive CCRT for N3-IIIB NSCLC could be expected if combining these targeting agents with RT.

As described above, the Surveillance, Epidemiology, and End Results (SEER) data demonstrated increased use of IMRT for patients with stage III NSCLC \[[@b15-crt-2014-131]\]. A radiation oncologists' practice environment can strongly influence utilization of the IMRT technique. Similarly, the reimbursement policies and practice settings were shown to have a great effect on utilization of IMRT for treatment of patients with breast cancer \[[@b23-crt-2014-131]\]. IMRT appears to have been utilized less frequently than necessary in Korea, mainly because the national health insurance system does not reimburse patients for this technique. The high cost of IMRT for lung cancer could be a considerable financial burden, resulting in financial toxicity \[[@b24-crt-2014-131],[@b25-crt-2014-131]\]. Therefore, careful and reasonable decision making with consideration of the cost effectiveness should become a crucially important issue for the optimal utilization of up-to-date technologies and resources. Future research efforts should be directed toward solving these issues and development of biological markers.

Conclusion
==========

The current study has several limitations, including a small number of patients, great heterogeneity in disease extent, and potential selection bias owing to the economic capacity of the patients. Nevertheless, the authors were able to demonstrate that IMRT was capable of delivering high radiation dose with no extra risk of lung toxicity in a definitive CCRT setting for treatment of N3-IIIB NSCLC patients, especially those with extensive disease, such as lower lobe primary tumor with SCN metastasis. Since the early occurrence of distant metastasis was a major pattern of disease progression, careful patient selection and optimal combinations of systemic treatments, including targeting agents, are necessary to improve clinical outcomes.
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###### 

Clinical characteristics according to radiotherapy technique

  Characteristic               3D-CRT (n=48)      IMRT (n=29)        p-value
  ---------------------------- ------------------ ------------------ ---------
  Age (yr)                     62 (44-72)         59 (40-80)         0.744
  Sex                                                                
   Male                        35 (72.9)          18 (62.1)          0.390
   Female                      13 (27.1)          11 (37.9)          
  Smoking history              34 (70.8)          17 (58.6)          0.272
  FEV~1~ (L)                   2.49 (1.17-3.90)   2.50 (1.46-3.71)   0.791
  ECOG performance                                                   
   0                           10 (20.8)          6 (20.7)           0.988
   1                           38 (79.2)          23 (79.3)          
  Primary site                                                       
   Upper-middle lobes          39 (81.3)          13 (44.8)          0.001
   Lower lobes                 9 (18.7)           16 (55.2)          
  Histology                                                          
   Adenocarcinoma              31 (64.6)          22 (75.9)          0.053
   Squamous cell carcinoma     15 (31.2)          3 (10.3)           
   Others                      2 (4.2)            4 (13.8)           
  Tumor size (cm)              3.8 (1.3-12.2)     3.7 (1.0-9.2)      0.785
  Clinical T classification                                          
   cT1-2                       34 (70.8)          23 (79.3)          0.411
   cT3-4                       14 (29.2)          6 (20.7)           
  N3 involvement region                                              
   Contralateral mediastinum   29 (60.4)          7 (24.1)           0.002
   Supraclavicular             26 (54.2)          24 (82.8)          0.011

Values are presented as median (range) or number (%). 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; FEV~1~, forced expiratory volume in 1 second; ECOG, Eastern Cooperative Oncology Group.

###### 

Dose-volume parameters according to radiotherapy techniques

  Variable             3D-CRT (n=48)          IMRT (n=29)          p-value
  -------------------- ---------------------- -------------------- ----------
  CTV (cm^3^)          279.3 (89.4-1,543.3)   357.5 (89.3-762.7)   0.706
  CTV                                                              
   \< 300 cm^3^        28 (59.3)              10 (34.5)            0.043
   ≥ 300 cm^3^         20 (41.7)              19 (65.5)            
  Total lung                                                       
   Mean dose (Gy)      18.4 (9.3-28.0)        19.6 (14.6-25.2)     0.031
   V~5~(%)             57.2 (29.8-72.9)       65.1 (48.4-90.0)     \< 0.001
   V~10~ (%)           48.6 (24.5-63.5)       51.8 (41.8-62.9)     0.107
   V~15~ (%)           40.6 (18.1-54.5)       42.3 (34.7-53.6)     0.052
   V~20~ (%)           32.8 (14.3-50.0)       35.6 (28.2-45.9)     0.061
  Esophagus                                                        
   Maximum dose (Gy)   67.1 (55.3-74.7)       68.4 (60.0-77.3)     0.007
   Mean dose (Gy)      33.2 (12.5-55.8)       35.1 (16.1-52.0)     0.111
   V~30~ (%)           52.1 (15.2-87.7)       55.9 (15.8-79.6)     0.520
   V~45~ (%)           44.2 (3.7-74.9)        48.8 (1.2-76.5)      0.526
  Spinal cord                                                      
   Maximum dose (Gy)   43.9 (10.5-57.4)       43.1 (32.3-48.4)     0.708
  Heart                                                            
   Median dose (Gy)    8.6 (0.5-42.4)         16.4 (1.5-35.0)      0.001

Values are presented as median (range) or number (%). 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; CTV, clinical target volume; V~D~, percentage volume of organ receiving ≥ D Gy.

###### 

Outcomes according to treatment groups

  Variable                   3D-CRT (n=48)    IMRT (n=29)      Overall (n=77)
  -------------------------- ---------------- ---------------- ----------------
  Disease progression        24 (50.0)        21 (72.4)        45 (58.4)
  Time to progression (mo)   9.1 (3.9-35.0)   6.0 (2.5-15.9)   8.2 (2.5-35.0)
  Patterns of failures                                         
   Locoregional              4 (8.3)          2 (6.9)          6 (7.8)
   Distant                   17 (35.4)        15 (51.7)        32 (41.6)
   Both                      3 (6.3)          4 (13.8)         7 (9.1)
  Esophagitis                                                  
   Grade ≤ 2                 41 (85.4)        21 (72.4)        62 (80.5)
   Grade 3                   7 (14.6)         8 (27.6)         15 (19.5)
  Pneumonitis                                                  
   Grade 1                   32 (66.7)        22 (75.9)        54 (70.1)
   Grade ≥ 2                 16 (33.3)        7 (24.1)         23 (29.9)

Values are presented as number (%) or median (range). 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy.

###### 

Prognostic factors affecting survival outcomes upon univariate analysis in patients with N3-positive stage IIIB non-small cell lung cancer

  Variable                         No.   PFS     OS      In-field LRC                   
  -------------------------------- ----- ------- ------- -------------- ------- ------- -------
  Treatment group                                                                       
   3D-CRT                          48    50.10   0.001   83.50          0.007   89.40   0.432
   IMRT                            29    19.30           61.70                  72.40   
  Sex                                                                                   
   Male                            53    42.50   0.229   71.00          0.311   83.40   0.740
   Female                          24    30.10           85.20                  87.50   
  Age (yr)                                                                              
   \< 60                           35    22.90   0.019   77.00          0.753   92.30   0.635
   ≥ 60                            42    54.00           74.50                  80.60   
  Histology                                                                             
   Adenocarcinoma                  53    28.70   0.002   75.60          0.160   83.70   0.636
   Squamous cell carcinoma         18    75.00           83.30                  86.70   
   Others                          6     16.70           44.40                  83.30   
  Clinical T classification                                                             
   cT1-2                           48    38.70   0.904   76.80          0.722   85.10   0.948
   cT3-4                           29    39.00           70.00                  85.20   
  SCN involvement                                                                       
   Yes                             50    34.20   0.320   75.30          0.894   83.50   0.686
   No                              27    46.30           74.50                  86.60   
  SCN from lower lobe                                                                   
   Yes                             16    23.50   0.160   60.60          0.019   80.00   0.856
   No                              61    42.20           79.10                  85.70   
  Clinical target volume (cm^3^)                                                        
   \< 300                          38    46.00   0.139   91.20          0.001   88.40   0.834
   ≥ 300                           39    31.00           59.10                  80.10   

PFS, progression-free survival; OS, overall survival; LRC, locoregional control; 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; SCN, supraclavicular lymph node.

###### 

Cox proportional hazards multivariate model for survival outcomes

  Variable              Progression-free survival   Overall survival                          
  --------------------- --------------------------- ------------------ ---------------------- -------
  Treatment group       2.498 (1.246-5.008)         0.010              2.160 (0.670-6.965)    0.197
  Age                   0.514 (0.280-0.943)         0.032              \-                     \-
  Histology             0.876 (0.490-1.564)         0.654              1.253 (0.657-2.390)    0.494
  SCN from lower lobe   0.872 (0.379-2.003)         0.747              1.554 (0.490-4.927)    0.454
  CTV (≥ 300 cm^3^)     1.549 (0.834-2.879)         0.166              4.665 (1.298-16.766)   0.018

HR, hazard ratio; CI, confidence interval; SCN, supraclavicular lymph node; CTV, clinical target volume.
